Plus Therapeutics (PSTV) Revenue & Revenue Breakdown
Plus Therapeutics Revenue Highlights
Latest Revenue (Y)
$4.91M
Main Segment (Y)
Grant
Main Geography (Y)
Product
Plus Therapeutics Revenue by Period
Plus Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $4.91M | 2093.30% |
| 2022-12-31 | $224.00K | 100.00% |
| 2021-12-31 | - | -100.00% |
| 2020-12-31 | $303.00K | -95.67% |
| 2019-12-31 | $7.00M | 134.60% |
| 2018-12-31 | $2.98M | -53.47% |
| 2017-12-31 | $6.41M | -43.66% |
| 2016-12-31 | $11.38M | -2.39% |
| 2015-12-31 | $11.66M | 53.45% |
| 2014-12-31 | $7.60M | -37.70% |
| 2013-12-31 | $12.20M | -15.90% |
| 2012-12-31 | $14.50M | 45.07% |
| 2011-12-31 | $10.00M | -5.94% |
| 2010-12-31 | $10.63M | 19.50% |
| 2009-12-31 | $8.89M | 96.40% |
| 2008-12-31 | $4.53M | -25.14% |
| 2007-12-31 | $6.05M | -23.69% |
| 2006-12-31 | $7.93M | 40.70% |
| 2005-12-31 | $5.63M | -17.37% |
| 2004-12-31 | $6.82M | -51.60% |
| 2003-12-31 | $14.09M | 53.70% |
| 2002-12-31 | $9.17M | 62.29% |
| 2001-12-31 | $5.65M | -9.65% |
| 2000-12-31 | $6.25M | 313.15% |
| 1999-12-31 | $1.51M | 100.00% |
| 1998-12-31 | - | - |
Plus Therapeutics generated $4.91M in revenue during NA 2023, up 2093.30% compared to the previous quarter, and up 164.70% compared to the same period a year ago.
Plus Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $1.68M | 27.72% |
| 2023-12-31 | $1.31M | 5.89% |
| 2023-09-30 | $1.24M | -33.12% |
| 2023-06-30 | $1.85M | 266.40% |
| 2023-03-31 | $506.00K | 125.89% |
| 2022-12-31 | $224.00K | 206.85% |
| 2022-09-30 | $73.00K | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | -100.00% |
| 2020-06-30 | $185.00K | 56.78% |
| 2020-03-31 | $118.00K | -90.07% |
| 2019-12-31 | $1.19M | -75.10% |
| 2019-09-30 | $4.77M | 1479.80% |
| 2019-06-30 | $302.00K | -79.03% |
| 2019-03-31 | $1.44M | -32.55% |
| 2018-12-31 | $2.13M | 62.73% |
| 2018-09-30 | $1.31M | -15.84% |
| 2018-06-30 | $1.56M | -5.40% |
| 2018-03-31 | $1.65M | 7.85% |
| 2017-12-31 | $1.53M | -13.82% |
| 2017-09-30 | $1.77M | 18.20% |
| 2017-06-30 | $1.50M | -6.77% |
| 2017-03-31 | $1.61M | -46.85% |
| 2016-12-31 | $3.03M | 15.98% |
| 2016-09-30 | $2.61M | -7.61% |
| 2016-06-30 | $2.83M | -3.19% |
| 2016-03-31 | $2.92M | -13.57% |
| 2015-12-31 | $3.38M | 36.29% |
| 2015-09-30 | $2.48M | -28.43% |
| 2015-06-30 | $3.46M | 47.53% |
| 2015-03-31 | $2.35M | -37.76% |
| 2014-12-31 | $3.77M | 241.70% |
| 2014-09-30 | $1.10M | -14.56% |
| 2014-06-30 | $1.29M | -9.97% |
| 2014-03-31 | $1.43M | -58.55% |
| 2013-12-31 | $3.46M | 27.63% |
| 2013-09-30 | $2.71M | 19.59% |
| 2013-06-30 | $2.27M | -39.68% |
| 2013-03-31 | $3.76M | -48.70% |
| 2012-12-31 | $7.33M | 456.69% |
| 2012-09-30 | $1.32M | -69.93% |
| 2012-06-30 | $4.38M | 194.88% |
| 2012-03-31 | $1.48M | 79.88% |
| 2011-12-31 | $825.00K | -61.43% |
| 2011-09-30 | $2.14M | -11.68% |
| 2011-06-30 | $2.42M | -6.74% |
| 2011-03-31 | $2.60M | -1.22% |
| 2010-12-31 | $2.63M | 73.07% |
| 2010-09-30 | $1.52M | -27.60% |
| 2010-06-30 | $2.10M | -52.42% |
| 2010-03-31 | $4.41M | 53.25% |
| 2009-12-31 | $2.88M | 106.83% |
| 2009-09-30 | $1.39M | -83.71% |
| 2009-06-30 | $8.54M | 344.84% |
| 2009-03-31 | $1.92M | -1216.28% |
| 2008-12-31 | $-172.00K | -107.41% |
| 2008-09-30 | $2.32M | 65.24% |
| 2008-06-30 | $1.40M | 817.65% |
| 2008-03-31 | $153.00K | 537.50% |
| 2007-12-31 | $24.00K | - |
Plus Therapeutics generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Plus Therapeutics Revenue Breakdown
Plus Therapeutics Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 19 | Dec 18 |
|---|---|---|---|
| Grant | $224.00K | - | - |
| Product | - | $901.00K | $2.67M |
| Consumable | - | - | $2.17M |
| Other Products | - | - | $277.00K |
| Device | - | - | $225.00K |
Plus Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 22: Grant (100.00%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Sep 23 | Mar 23 | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|
| Grant | $1.28M | $1.24M | $506.00K | - | - | - | - | - |
| Other Products | - | - | - | $40.00K | $67.00K | $65.00K | $66.00K | $78.00K |
| Consumable | - | - | - | $663.00K | $324.00K | $692.00K | $594.00K | $559.00K |
| Product | - | - | - | $703.00K | - | - | - | - |
| Device | - | - | - | - | $31.00K | $101.00K | $94.00K | $94.00K |
Plus Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Grant (100.00%).
Plus Therapeutics Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 19 | Dec 18 |
|---|---|---|
| Product | $901.00K | - |
| Americas | - | $293.00K |
| JAPAN | - | $2.06M |
| E M E A | - | $270.00K |
| Asia Pacific | - | $50.00K |
Plus Therapeutics's latest annual revenue breakdown by geography, as of Dec 19: Product (100.00%).
Quarterly Revenue by Country
| Country | Mar 19 | Dec 18 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|
| JAPAN | $419.00K | $365.00K | $535.00K | $581.00K | $578.00K |
| Product | $703.00K | - | - | - | - |
| Other Products | $40.00K | - | - | - | - |
| Consumable | $663.00K | - | - | - | - |
| E M E A | $150.00K | $8.00K | $114.00K | $57.00K | $90.00K |
| Asia Pacific | $70.00K | $5.00K | $10.00K | $16.00K | $18.00K |
| Americas | $64.00K | $44.00K | $199.00K | $6.00K | $45.00K |
Plus Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 19: Product (33.33%), Consumable (31.44%), JAPAN (19.87%), E M E A (7.11%), Asia Pacific (3.32%), Americas (3.03%), and Other Products (1.90%).
Plus Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PSTV | Plus Therapeutics | $4.91M | - |
| ADTX | Aditxt | $645.18K | $44.28K |
| VCNX | Vaccinex | $570.00K | $232.00K |
| PALI | Palisade Bio | $250.00K | - |
| VRAX | Virax Biolabs Group | $8.56K | $76.50K |
| NRBO | NeuroBo Pharmaceuticals | $7.00K | - |
| CYTO | Altamira Therapeutics | - | $52.73K |
| TARA | Protara Therapeutics | - | - |
| ZURA | Zura Bio | - | - |
| REVB | Revelation Biosciences | - | - |
| FWBI | Entero Therapeutics | - | - |
| DRMA | Dermata Therapeutics | - | - |
| MNPR | Monopar Therapeutics | - | - |
| HOTH | Hoth Therapeutics | - | - |
| ATXI | Avenue Therapeutics | - | - |
| CFRX | ContraFect | - | - |
| IMMX | Immix Biopharma | - | - |
| SRZN | Surrozen | - | - |
| ENVB | Enveric Biosciences | - | - |
| QNRX | Quoin Pharmaceuticals | - | - |
PSTV Revenue FAQ
What is Plus Therapeutics’s yearly revenue?
Plus Therapeutics's yearly revenue for 2023 was $4.91M, representing an increase of 2093.30% compared to 2022. The company's yearly revenue for 2022 was $224K, representing an increase of 100.00% compared to 2021. PSTV's yearly revenue for 2021 was $0, representing a decrease of -100.00% compared to 2020.
What is Plus Therapeutics’s quarterly revenue?
Plus Therapeutics's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $1.68M, a 27.72% increase from the previous quarter (Q4 2023), and a 231.42% increase year-over-year (Q1 2023). PSTV's quarterly revenue for Q4 2023 was $1.31M, a 5.89% increase from the previous quarter (Q3 2023), and a 486.16% increase year-over-year (Q4 2022).
What is Plus Therapeutics’s revenue growth rate?
Plus Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was -29.79%.
What are Plus Therapeutics’s revenue streams?
Plus Therapeutics's revenue streams in c 22 are Grant
What is Plus Therapeutics’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Plus Therapeutics was Grant. This segment made a revenue of $224K, representing 100.00% of the company's total revenue.